GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » 6-1 Month Momentum %

Acura Pharmaceuticals (Acura Pharmaceuticals) 6-1 Month Momentum % : 733.33% (As of Apr. 28, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-28), Acura Pharmaceuticals's 6-1 Month Momentum % is 733.33%.

The industry rank for Acura Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

ACUR's 6-1 Month Momentum % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.415 vs ACUR: 733.33

Competitive Comparison of Acura Pharmaceuticals's 6-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's 6-1 Month Momentum % falls into.



Acura Pharmaceuticals  (OTCPK:ACUR) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acura Pharmaceuticals  (OTCPK:ACUR) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Acura Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.
Executives
Bruce F Wesson director 1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly director C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross director 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh officer: VP, Corporate Development
Immanuel Thangaraj director 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser officer: VP, Treasurer & Controller C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones officer: President & CEO C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko officer: VP Pharmaceutical Sciences APT C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens officer: Senior VP & CFO C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc 10 percent owner 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc 10 percent owner C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte 10 percent owner 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P 10 percent owner 610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc 10 percent owner 680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020

Acura Pharmaceuticals (Acura Pharmaceuticals) Headlines

From GuruFocus

Acura Pharmaceuticals Licenses LIMITx™ LTX-03

By Marketwired Marketwired 07-03-2019

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx� LTX-03

By GuruFocusNews GuruFocusNews 03-01-2022

Acura Pharmaceuticals Provides Development Update on LTX-03

By Marketwired Marketwired 06-07-2021

Acura Pharmaceuticals, Inc. Restructures Debt Obligations

By Marketwired Marketwired 10-10-2018

Acura Pharmaceuticals Announces Conversion of Debt

By Marketwired Marketwired 06-14-2021